BCR-ABL SIGNALING A new STATus in CML

被引：0

作者：

Fabbro, Doriano ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Basel, Switzerland

来源：

NATURE CHEMICAL BIOLOGY | 2012年 / 8卷 / 03期

关键词：

CHRONIC MYELOID-LEUKEMIA; BCR/ABL;

D O I：

10.1038/nchembio.900

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：228 / 229

页数：2

共 50 条

[41] Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients [J].

Cai, Ann ;

Keskin, Derin B. ;

DeLuca, David S. ;

Alonso, Anselmo ;

Zhang, Wandi ;

Zhang, Guang Lan ;

Hammond, Naa Norkor ;

Nardi, Valentina ;

Stone, Richard M. ;

Neuberg, Donna ;

Sidney, John ;

Brusic, Vladimir ;

Wu, Catherine J. .

CLINICAL CANCER RESEARCH, 2012, 18 (20) :5761-5772

[42] BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report [J].

Ostendorf, Benjamin N. ;

Nogai, Hendrik ;

Baldus, Claudia D. ;

Burmeister, Thomas ;

Arnold, Renate .

BIOMARKER INSIGHTS, 2015, 10 :25-28

[43] Design and Synthesis of New Heterocyclic Bcr-Abl Inhibitors [J].

Chen, Yong-Fei ;

Ni, Nanting ;

Li, Minyong ;

Xu, Peng-Fei ;

Wang, Binghe .

HETEROCYCLIC COMMUNICATIONS, 2010, 16 (2-3) :123-135

[44] Allosteric inhibition of BCR-ABL [J].

Hassan, A. Quamrul ;

Sharma, Sreenath V. ;

Warmuth, Markus .

CELL CYCLE, 2010, 9 (18) :3710-3714

[45] Bcr-Abl Inhibitory Activities of Imatinib Derivatives [J].

Hou, Bao-Long ;

Yan, Jiaxu ;

Liu, Rongrong ;

Lv, Longquan ;

Feng, Ruirui ;

Yang, Xiumei ;

Guo, Guanlin ;

Wang, Cuiling .

LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (17) :4085-4094

[46] Depression of oncogenecity by dephosphorylating and degrading BCR-ABL [J].

Gao, Miao ;

Huang, Zheng-Lan ;

Tao, Kun ;

Xiao, Qing ;

Wang, Xin ;

Cao, Wei-Xi ;

Xu, Min ;

Hu, Jing ;

Feng, Wen-Li .

ONCOTARGET, 2017, 8 (02) :3304-3314

[47] Aleukemic bcr-abl positive granulocytic sarcoma [J].

Kuan, Jew-Win ;

Pathmanathan, Rajadurai ;

Chang, Kian-Meng ;

Tan, Sen-Moi .

LEUKEMIA RESEARCH, 2009, 33 (11) :1574-1577

[48] Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors [J].

Xu, Xiao-Liang ;

Cao, Yu-Jing ;

Zhang, Wen ;

Rao, Guo-Wu .

CURRENT MEDICINAL CHEMISTRY, 2022, 29 (17) :3050-3078

[49] Life and Death of Leukemic Cells Under Bcr-Abl Signaling Control [J].

Kuroda, Junya ;

Taniwaki, Masafumi .

CURRENT CANCER THERAPY REVIEWS, 2009, 5 (04) :303-309

[50] BCR-ABL ONCOPROTEINS BIND DIRECTLY TO ACTIVATORS OF THE RAS SIGNALING PATHWAY [J].

PUIL, L ;

LIU, JX ;

GISH, G ;

MBAMALU, G ;

BOWTELL, D ;

PELICCI, PG ;

ARLINGHAUS, R ;

PAWSON, T .

EMBO JOURNAL, 1994, 13 (04) :764-773

← 1 2 3 4 5 →